Advertisement

The impact of obesity and insulin resistance on thyroid cancer: A systematic review

      Highlights

      • The prevalence of thyroid cancer has increased in recent years.
      • This phenomenon may reflect improved detection.
      • There is a significant association between thyroid cancer and obesity.
      • Insulin resistance and hyperinsulinemia may be the pathophysiological links between thyroid cancer and obesity.

      Abstract

      In recent decades, there has been a marked increase in the prevalence of thyroid cancer. This phenomenon has paralleled the increase in the prevalence of obesity worldwide, which is associated with insulin resistance. Associations between these entities have been hypothesized, mainly for older and female populations, but they remain unclear. The aim of this article is to systematically review the literature in an attempt to determine whether the increase in the prevalence of thyroid cancer is due to obesity or due only to improved detection with the better imaging techniques available. A thorough literature search on PubMed and application of selection criteria identified 15 appropriate studies. The detailed analysis of the data from these studies indicated that there is a suggestive association between thyroid cancer, obesity, insulin resistance and hyperinsulinemia for both genders. Therefore, the increased prevalence of thyroid cancer is not dependent on improved detection only. Further research should be performed for complete understanding of the pathophysiological associations, especially regarding adipose tissue and genetics, but also for the improvement of preventive public health policies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Oberman B.
        • Khaku A.
        • Camachov F.
        • Goldenberg D.
        Relationship between obesity, diabetes and the risk of thyroid cancer.
        Am. J. Otolaryngol. 2015; 36: 535-541
        • Paschou S.A.
        • Vryonidou A.
        • Goulis D.G.
        Thyroid nodules: a guide to assessment, treatment and follow-up.
        Maturitas. 2017; 96: 1-9
        • Vlassopoulou V.
        • Vryonidou A.
        • Paschou S.A.
        • Ioannidis D.
        • Koletti A.
        • Klonaris N.
        • Katsoulis K.
        • Rontogianni D.
        • Vasilopoulos C.
        • Tsagarakis S.
        • Tzavara I.
        No considerable changes in papillary thyroid microcarcinoma characteristics over a 30-year time period.
        BMC Res. Notes. 2016; 29: 252
        • Shin H.Y.
        • Jee Y.H.
        • Cho E.R.
        Body mass index and incidence of thyroid cancer in Korea: the Korean cancer prevention study-II.
        J. Cancer Res. Clin. Oncol. 2017; 143: 143-149
        • Iftikhar H.
        • Ikram M.
        • Muhammad A.Y.
        • Nathani K.R.
        Unusual presentation of differentiated thyroid Cancer metastasis.
        Int. Arch. Otorhinolaryngol. 2018; 22: 167-170
        • Schmid D.
        • Ricci C.
        • Behrens G.
        • Leitzmann M.F.
        Adiposity and risk of thyroid cancer: a systematic review and meta-analysis.
        Obes. Rev. 2015; 16: 1042-1054
        • Rezzónico J.N.
        • Rezzónico M.
        • Pusiol E.
        • Pitoia F.
        • Niepomniszcze H.
        Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma.
        Metab. Syndr. Relat. Disord. 2009; 7: 375-380
        • Childs B.G.
        • Durik M.
        • Baker D.J.
        • van Deursen J.M.
        Cellular senescence in aging and age-related disease: from mechanisms to therapy.
        Nat. Med. 2015; 21: 1424-1435
        • Tsatsoulis A.
        The role of insulin resistance/hyperinsulinism on the rising trend of thyroid and adrenal nodular disease in the current environment.
        J. Clin. Med. 2018; 7: 37
        • Shargorodsky M.
        • Wainstein G.
        • Gavish E.
        • Leibovitz E.
        • Matas D.
        • Zimlichman R.
        Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
        Am. J. Hematol. 2003; 16: 617-622
        • Grodski S.
        • Brown T.
        • Sidhu S.
        • Gill A.
        • Robinson B.
        • Learoyd D.
        • Sywak M.
        • Reeve T.
        • Delbridge L.
        Increasing incidence of thyroid cancer is due to increased pathologic detection.
        Surgery. 2008; 144: 1038-1943
        • Chen A.Y.
        • Jemal A.
        • Elizabeth M.
        Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005.
        Cancer. 2009; 115: 3801-3807
        • Morris L.G.T.
        • Myssiorek D.
        Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis.
        Am. J. Surg. 2010; 200: 454-461
        • Engeland A.
        • Tretli S.
        • Akslen L.A.
        • Bjørge T.
        Body size and thyroid cancer in two million Norwegian men and women.
        Br. J. Cancer. 2006; 95: 366-370
        • Kitahara C.M.
        • Platz E.A.
        • Freeman L.B.
        • Hsing A.W.
        • Linet M.S.
        • Park Y.
        • Schairer C.
        • Schatzkin A.
        • Shikany J.M.
        • de González A.B.
        Obesity and thyroid cancer risk among U.S. Men and women: a pooled analysis of 5 prospective studies.
        Cancer Epidemiol. Biomark. Prev. 2011; 20: 464-472
        • Han J.M.
        • Kim T.Y.
        • Jeon M.J.
        • Yim J.H.
        • Kim W.G.
        • Song D.E.
        • Hong S.J.
        • Bae S.J.
        • Kim H.K.
        • Shin M.H.
        • et al.
        Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population.
        Eur. J. Endocrinol. 2013; 168: 879-886
        • Rotondi M.
        • Castagna M.G.
        • Cappelli C.
        • Ciuoli C.
        • Coperchini F.
        • Chiofalo F.
        • Maino F.
        • Palmitesta P.
        • Chiovato L.
        • Pacinib F.
        Obesity does not modify the risk of differentiated thyroid cancer in a cytological series of thyroid nodules.
        Eur. Thyroid J. 2016; 5: 125-131
        • Buscemi S.
        • Massenti F.M.
        • Vasto S.
        • Galvano F.
        • Buscemi C.
        • Corleo D.
        • Barile A.M.
        • Rosafio G.
        • Rini N.
        • Giordano C.
        Association of obesity and diabetes with thyroid nodules.
        Endocrine. 2018; 60: 339-347
        • Cheng S.P.
        • Chi C.W.
        • Tzen C.Y.
        • Yang T.L.
        • Lee J.J.
        • Liu T.P.
        • Liu C.L.
        Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma.
        Surgery. 2010; 147: 847-853
        • Paes J.E.
        • Hua K.
        • Nagy R.
        • Kloos R.T.
        • Jarjoura D.
        • Ringe M.D.
        The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study.
        J. Clin. Endocrinol. Metab. 2010; 95: 4244-4250
        • Pitoia F.
        • Abelleira E.
        • Bueno F.
        • Urciuoli C.
        • Schmidt A.
        • Niepomniszcze H.
        Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer.
        Endocrine. 2015; 48: 894-901
        • Bae M.J.
        • Kim S.S.
        • Kim W.J.
        • Yi Y.S.
        • Jeon Y.K.
        • Kim B.H.
        • Lee B.J.
        • Lee J.C.
        • Kim I.J.
        • Wang S.G.
        • et al.
        High prevalence of papillary thyroid cancer in Korean women with insulin resistance.
        Head Neck. 2016; 38: 66-71
        • Davies L.
        • Welch H.G.
        Increasing incidence of thyroid cancer in the United States, 1973–2002.
        JAMA. 2006; 295: 2164-2167
        • Larson S.D.
        • Jackson L.N.
        • Riall T.S.
        • Uchida T.
        • Thomas R.P.
        • Qiu S.
        • Evers B.M.
        Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.
        J. Am. Coll. Surg. 2007; 204: 764-775
        • Mack W.J.
        • Preston-Martin S.
        • Bernstein L.
        • Qian D.
        Lifestyle and other risk factors for thyroid cancer in Los Angeles County females.
        Ann. Epidemiol. 2002; 12: 395-401
        • Kitahara C.M.
        • Farkas D.K.
        • Jørgensen J.O.L.
        • Cronin-Fenton D.
        • Sørensen H.T.
        Benign thyroid diseases and risk of thyroid cancer: a nationwide cohort study.
        J. Clin. Endocrinol. Metab. 2019; 103: 2216-2224
        • Kitahara C.M.
        • McCullough M.L.
        • Franceschi S.
        • Rinaldi S.
        • Wolk A.
        • Neta G.
        • Adami H.O.
        • Anderson K.
        • Andreotti G.
        • Freeman L.E.B.
        • et al.
        Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies.
        Thyroid. 2016; 26: 306-318
        • Adab P.
        • Pallan M.
        • Whincup P.H.
        Is BMI the best measure of obesity?.
        Br. Med. J. 2018; 360k1274
        • Hita-Contreras F.
        Traditional body mass index cut-offs in older people: time for a rethink with altered fat distribution, sarcopenia and shrinking height.
        Maturitas. 2018; 113: A1-A2
      1. American Thyroid Association, Thyroid & Weight.
        2016 (Accessed 21 February 2019)
        • Malaguarnera R.
        • Frasca F.
        • Garozzo A.
        • Gianì F.
        • Pandini G.
        • Vella V.
        • Vigneri R.
        • Belfiore A.
        Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid.
        J. Clin. Endocrinol. Metab. 2001; 96: 766-774
        • Garofalo C.
        • Surmacz E.
        Leptin and cancer.
        J. Cell. Physiol. 2006; 207: 12-22
        • Lipsey C.C.
        • Harbuzariu A.
        • Daley-Brown D.
        • Gonzalez-Perez R.R.
        Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer.
        World J. Methodol. 2016; 6: 43-55
        • Dutta D.
        • Ghosh S.
        • Pandit K.
        • Mukhopadhyay P.
        • Chowdhury S.
        Leptin and cancer: Pathogenesis and modulation.
        Indian J. Endocrinol. Metab. 2012; 16: 596-600
        • Kim M.R.
        • Kim S.S.
        • Huh J.E.
        • Lee B.J.
        • Lee J.C.
        • Jeon Y.K.
        • Kim B.H.
        • Kim S.J.
        • Wang S.G.
        • Kim Y.K.
        • et al.
        Neck circumference correlates with tumor size and lateral lymph node metastasis in men with small papillary thyroid carcinoma.
        Korean J. Intern. Med. 2013; 28: 62-71
        • Kitahara C.M.
        • Platz E.A.
        • Park Y.
        • Hollenbeck A.R.
        • Schatzkin A.
        • de González A.B.
        Body fat distribution, weight change during adulthood, and thyroid cancer risk in the NIH-AARP Diet and Health Study.
        Int. J. Cancer. 2012; 130: 1411-1419
        • Vella V.
        • Sciacca L.
        • Pandini G.
        • Mineo R.
        • Squatrito S.
        • Vigneri R.
        • Belfiore A.
        The IGF system in thyroid cancer: new concepts.
        Mol. Pathol. 2001; 54: 121-124
        • Brennan A.
        • Mantzoros C.
        Drug Insight: the role of leptin in human physiology and pathophysiology — emerging clinical applications.
        Nat. Clin. Pract. Endocrinol. Metab. 2006; 2: 318-327
        • Wu J.
        • Yu E.
        Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
        Cancer Metastasis Rev. 2014; 33: 607-617
        • LeRoith D.
        • Roberts Jr., C.T.
        The insulin-like growth factor system and cancer.
        Cancer Lett. 2003; 195: 127-137
        • Maiorano E.
        • Ciampolillo A.
        • Viale G.
        • Maisonneuve P.
        • Ambrosi A.
        • Triggiani V.
        • Marra E.
        • Perlino E.
        Insulin-like growth factor 1 expression in thyroid tumors.
        Appl. Immunohistochem. Mol. Morphol. 2000; 8: 110-119
        • Fu P.
        • Thompson J.A.
        • Leeding K.S.
        • Bach L.A.
        Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells.
        J. Cell. Biochem. 2007; 100: 58-68
        • Platz E.A.
        • De Marzo A.M.
        Epidemiology of in ammation and prostate cancer.
        J. Urol. 2004; 171: S36-S40
        • Kaaks R.
        • Lukanova A.
        • Sommersberg B.
        Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review.
        Prostate Cancer Prostatic Dis. 2000; 3: 157-172
        • Ghanim H.
        • Aljada A.
        • Daoud N.
        • Deopurkar R.
        • Chaudhuri A.
        • Dandona P.
        Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects.
        Diabetologia. 2007; 50: 278-285
        • Sun J.
        • Hsu F.C.
        • Turner A.R.
        • Zheng S.L.
        • Chang B.L.
        • Liu W.
        • Isaacs W.B.
        • Xu J.
        Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk.
        Prostate. 2006; 66: 728-737
        • Xu J.
        • Lowey J.
        • Wiklund F.
        • Sun J.
        • Lindmark F.
        • Hsu F.C.
        • Dimitrov L.
        • Chang B.
        • Turner A.R.
        • Liu W.
        • et al.
        The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.
        Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2563-2568
        • Lindmark F.
        • Zheng S.L.
        • Wiklund F.
        • Bälter K.A.
        • Sun J.
        • Chang B.
        • Hedelin M.
        • Clark J.
        • Johansson J.E.
        • Meyers D.A.
        • et al.
        Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.
        Br. J. Cancer. 2005; 93: 493-497
        • Shoelson S.E.
        • Lee J.
        • Goldfine A.B.
        Inflammation and insulin resistance.
        J. Clin. Invest. 2006; 116: 1793-1801
        • Fradet V.
        • Lessard L.
        • Begin L.R.
        • Karakiewicz P.
        • Masson A.M.
        • Saad F.
        Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
        Clin. Cancer Res. 2004; 10: 8460-8464
        • Concetti J.
        • Wilson C.L.
        NFKB1 and cancer: friend or foe?.
        Cells. 2018; 7: 133
        • Dandona P.
        • Aljada A.
        • Mohanty P.
        • Ghanim H.
        • Hamouda W.
        • Assian E.
        • Ahmad S.
        Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?.
        J. Clin. Endocrinol. Metab. 2001; 86: 3257-3265
        • Lemoine N.R.
        • Mayall E.S.
        • Wyllie F.S.
        • Williams E.D.
        • Goyns M.
        • Stringer B.
        • Wynford-Thomas D.
        High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
        Oncogene. 1989; 4: 159-164
        • Kimura E.T.
        • Nikiforova M.N.
        • Zhu Z.
        • Knauf J.A.
        • Nikiforov Y.E.
        • Fagin J.A.
        High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
        Cancer Res. 2003; 63: 1454-1457
        • Alsina J.
        • Alsina R.
        • Güleç S.
        A concise atlas of thyroid cancer next-generation sequencing panel ThyroSeq v.2.
        Mol. Imaging Radionucl. Ther. 2017; 26: 102-117
        • Esapa C.T.
        • Johnson S.J.
        • Kendall-Taylor P.
        • Lennard T.W.
        • Harris P.E.
        Prevalence of Ras mutations in thyroid neoplasia.
        Clin. Endocrinol. (Oxf.). 1999; 50: 529-535
        • Boucher J.
        • Kleinridders A.
        • Kahn C.R.
        Insulin receptor signaling in normal and insulin-resistant states.
        Cold Spring Harb. Perspect. Biol. 2014; 6a009191